Novel genetic and epigenetic alterations in ... - Ous-research.no

References196. Honda S, Haruta M, Sugawara W, Sasaki F, Ohira M, Matsunaga T, Yamaoka H,Horie H, Ohnuma N, Nakagawara A, Hiyama E, Todo S, Kaneko Y (2008) Themethylation status of RASSF1A promoter predicts responsiveness tochemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer123(5): 1117-1125197. Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzynski DL, AssaadAM, Mansukhani M, Reuter VE, Bosl GJ, Chaganti RS, Murty VV (2004) Role ofpromoter hypermethylation in Cisplatin treatment response of male germ celltumors. Mol Cancer 3 16198. Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman L,Sobrero A, Douillard JY (2007) Endpoints in adjuvant treatment trials: asystematic review of the literature in colon cancer and proposed definitionsfor future trials. J Natl Cancer Inst 99(13): 998-1003199. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R,Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, BlankeCD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De GA (2005)Disease-free survival versus overall survival as a primary end point foradjuvant colon cancer studies: individual patient data from 20,898 patients on18 randomized trials. J Clin Oncol 23(34): 8664-8670200. Platell CF, Semmens JB (2004) Review of survival curves for colorectal cancer.Dis Colon Rectum 47(12): 2070-2075201. Greenman C, Wooster R, Futreal PA, Stratton MR, Easton DF (2006) Statisticalanalysis of pathogenicity of somatic mutations in cancer. Genetics 173(4):2187-2198202. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, LearyRJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD,Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G,Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE(2006) The consensus coding sequences of human breast and colorectalcancers. Science 314(5797): 268-274203. Torkamani A, Schork NJ (2008) Prediction of cancer driver mutations in proteinkinases. Cancer Res 68(6): 1675-1682204. Duval A, Rolland S, Compoint A, Tubacher E, Iacopetta B, Thomas G, Hamelin R(2001) Evolution of instability at coding and non-coding repeat sequences inhuman MSI-H colorectal cancers. Hum Mol Genet 10(5): 513-518205. Duval A, Hamelin R (2002) Mutations at coding repeat sequences in mismatchrepair-deficient human cancers: toward a new concept of target genes forinstability. Cancer Res 62(9): 2447-245484